CL2021001179A1 - Anticuerpos específicos para tl1a y ácidos nucleicos que los codifican (divisional de la solicitud no. 201801596). - Google Patents

Anticuerpos específicos para tl1a y ácidos nucleicos que los codifican (divisional de la solicitud no. 201801596).

Info

Publication number
CL2021001179A1
CL2021001179A1 CL2021001179A CL2021001179A CL2021001179A1 CL 2021001179 A1 CL2021001179 A1 CL 2021001179A1 CL 2021001179 A CL2021001179 A CL 2021001179A CL 2021001179 A CL2021001179 A CL 2021001179A CL 2021001179 A1 CL2021001179 A1 CL 2021001179A1
Authority
CL
Chile
Prior art keywords
tl1a
nucleic acids
divisional
acids encoding
application
Prior art date
Application number
CL2021001179A
Other languages
English (en)
Inventor
Hailing Hsu
Gunasekaran Kannan
Kenneth W Walker
Michelle Hortter
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2016/052006 external-priority patent/WO2017049004A1/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2021001179A1 publication Critical patent/CL2021001179A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Anticuerpos específicos para TL1A y ácidos nucleicos que los codifican.
CL2021001179A 2015-12-16 2021-05-05 Anticuerpos específicos para tl1a y ácidos nucleicos que los codifican (divisional de la solicitud no. 201801596). CL2021001179A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562268432P 2015-12-16 2015-12-16
US201662333063P 2016-05-06 2016-05-06
PCT/US2016/052006 WO2017049004A1 (en) 2015-09-15 2016-09-15 Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof

Publications (1)

Publication Number Publication Date
CL2021001179A1 true CL2021001179A1 (es) 2021-11-19

Family

ID=59057540

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2018001596A CL2018001596A1 (es) 2015-12-16 2018-06-14 Proteínas de unión al antígeno bispecífico de anti-tl1a/anti-tnf-a y sus usos
CL2021001179A CL2021001179A1 (es) 2015-12-16 2021-05-05 Anticuerpos específicos para tl1a y ácidos nucleicos que los codifican (divisional de la solicitud no. 201801596).
CL2023002597A CL2023002597A1 (es) 2015-12-16 2023-09-01 Proteínas de unión al antígeno bispecífico de anti-tl1a/anti-tnf-alfa

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2018001596A CL2018001596A1 (es) 2015-12-16 2018-06-14 Proteínas de unión al antígeno bispecífico de anti-tl1a/anti-tnf-a y sus usos

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2023002597A CL2023002597A1 (es) 2015-12-16 2023-09-01 Proteínas de unión al antígeno bispecífico de anti-tl1a/anti-tnf-alfa

Country Status (24)

Country Link
US (2) US11104745B2 (es)
EP (1) EP3390444A1 (es)
JP (1) JP7263007B2 (es)
KR (1) KR20180099723A (es)
CN (1) CN109311971A (es)
AU (2) AU2016370659B2 (es)
BR (1) BR112018012096A2 (es)
CA (1) CA3008267A1 (es)
CL (3) CL2018001596A1 (es)
CO (1) CO2018007355A2 (es)
CR (1) CR20180365A (es)
EA (1) EA201891322A1 (es)
IL (1) IL259847A (es)
JO (1) JO3816B1 (es)
MA (1) MA44060A (es)
MX (1) MX2018007424A (es)
PH (1) PH12018501284A1 (es)
SG (2) SG10201912002YA (es)
TN (1) TN2019000275A1 (es)
TW (1) TWI799368B (es)
UA (1) UA124305C2 (es)
UY (1) UY37027A (es)
WO (1) WO2017106383A1 (es)
ZA (1) ZA201904491B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
EA035018B1 (ru) 2011-09-30 2020-04-17 Тева Фармасьютикал Австралия Пти Лтд. АНТИТЕЛА К TL1a И ИХ ПРИМЕНЕНИЕ
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
KR20210157418A (ko) 2013-03-27 2021-12-28 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
EP3430172A4 (en) 2016-03-17 2019-08-21 Cedars-Sinai Medical Center METHOD FOR DIAGNOSIS OF INFLAMMATORY ENDURANCE THROUGH RNASET2
SG11201903737PA (en) 2016-10-26 2019-05-30 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
TW201904588A (zh) * 2017-06-25 2019-02-01 美商西雅圖免疫公司 引導及導航控制蛋白質之製造及使用方法
EP3456738A1 (en) 2017-09-19 2019-03-20 Tillotts Pharma Ag Antibody variants
WO2019136241A1 (en) * 2018-01-05 2019-07-11 Modernatx, Inc. Polynucleotides encoding anti-chikungunya virus antibodies
AU2019261426A1 (en) 2018-04-25 2020-12-03 Cedars Sinai Medical Center Optimized anti-TL1A antibodies
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
KR20220088529A (ko) * 2019-05-14 2022-06-27 프로메테우스 바이오사이언시즈, 인크. Tl1a 환자 선택 방법, 시스템 및 장치
BR112022000416A2 (pt) * 2019-07-11 2022-03-03 Wuhan Yzy Biopharma Co Ltd Anticorpo biespecífico, composição farmacêutica, conjugado, polinucleotídeo, célula e usos do anticorpo biespecífico
JP2022540806A (ja) 2019-07-19 2022-09-20 オンコレスポンス，インク． 免疫調節抗体およびその使用方法
CN116063517A (zh) 2019-10-24 2023-05-05 普罗米修斯生物科学公司 Tnf样配体1a(tl1a)的人源化抗体及其用途
CN113121696A (zh) * 2019-12-31 2021-07-16 周易 Fab改造诱导形成的双特异性抗体及其制备方法和用途
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
EP4126960A1 (en) * 2020-04-02 2023-02-08 La Jolla Institute for Immunology Methods and combinations for dual targeting of tnf family members
JP2023526469A (ja) * 2020-05-20 2023-06-21 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク ＳＡＲＳ－ＣｏＶ－２に対する強力な中和抗体、その生成および使用
CA3183367A1 (en) 2020-07-06 2022-01-13 Gevorg GRIGORYAN Antigen binding molecules targeting sars-cov-2
CN116348487A (zh) 2020-07-23 2023-06-27 欧萨尔普罗席纳有限公司 抗淀粉样β抗体
WO2022040466A1 (en) * 2020-08-20 2022-02-24 Amgen Inc. Antigen binding proteins with non-canonical disulfide in fab region
KR20230058434A (ko) 2020-08-26 2023-05-03 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 SARS-CoV-2를 표적으로 하는 항원 결합 분자

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
JP3202999B2 (ja) 1991-01-31 2001-08-27 協和醗酵工業株式会社 肝移行性リポソーム製剤
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US7820798B2 (en) 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
CA2616914C (en) 1996-12-03 2012-05-29 Abgenix, Inc. Egfr-binding antibody
AU760549B2 (en) 1998-04-03 2003-05-15 University Of Iowa Research Foundation, The Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
TR200102715T2 (tr) 1999-03-25 2002-09-23 Knoll Gmbh Beşeri IL-12'yi bağlayan beşeri antikorlar ve bunları üretmek için yöntemler.
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
MXPA02001264A (es) 1999-08-04 2002-07-22 Amgen Inc Fhm, nuevo miembro de la familia de supergenes de ligando de factor de necrosis tumoral.
ES2347239T3 (es) 2002-12-02 2010-10-27 Amgen Fremont Inc. Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
CA2536086C (en) 2003-08-20 2013-03-19 University Of Miami Inhibition of dr3 in the treatment of allergic lung inflammation
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20110217310A1 (en) 2007-01-10 2011-09-08 Siegel Richard M Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology
EP2220122A2 (en) 2007-11-13 2010-08-25 Teva Biopharmaceuticals USA, Inc. Humanized antibodies against tl1a
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
ES2828627T3 (es) 2008-04-25 2021-05-27 Kyowa Kirin Co Ltd Anticuerpo multivalente estable
AU2010233995A1 (en) 2009-04-07 2011-09-08 Roche Glycart Ag Bispecific anti-ErbB-2/anti-c-Met antibodies
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
JO3375B1 (ar) 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
EP2654792A4 (en) 2010-12-22 2016-05-11 Abbvie Inc HALF IMMUNOGLOBULIN BINDING PROTEINS AND USES THEREOF
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
KR20140104344A (ko) 2011-05-20 2014-08-28 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 시크리터리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시스 Ｔ 세포 매개성 질병의 병증을 개선하기 위한 ｔｌ１ａ-ｄｒ３의 상호작용의 차단 및 그것의 항체
CA2846432A1 (en) 2011-09-23 2013-03-28 Amgen Research (Munich) Gmbh Bispecific binding molecules for 5t4 and cd3
EA035018B1 (ru) 2011-09-30 2020-04-17 Тева Фармасьютикал Австралия Пти Лтд. АНТИТЕЛА К TL1a И ИХ ПРИМЕНЕНИЕ
CN104884473B (zh) 2012-05-22 2019-12-03 百时美施贵宝公司 Il-17a/f il-23双特异性抗体及其应用
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
RU2720472C2 (ru) 2012-11-28 2020-04-30 Займворкс Инк. Сконструированные пары тяжелая-легкая цепи иммуноглобулина и их применение
CN105102067B (zh) 2013-01-02 2020-03-03 艾科诺斯科技股份有限公司 结合tl1a的抗体及其用途
TW201444867A (zh) 2013-03-08 2014-12-01 Lilly Co Eli 抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
WO2014144600A2 (en) * 2013-03-15 2014-09-18 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
CN105189557A (zh) 2013-03-15 2015-12-23 默克专利有限公司 四价双特异性抗体
UA118028C2 (uk) * 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
SG10201810298VA (en) 2013-11-13 2018-12-28 Pfizer Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
US20160052006A1 (en) 2013-11-22 2016-02-25 Sheila S. Pirtle Spray Bottle

Also Published As

Publication number Publication date
US20220213226A1 (en) 2022-07-07
CL2018001596A1 (es) 2018-09-28
UA124305C2 (uk) 2021-08-25
US20190119407A1 (en) 2019-04-25
JP7263007B2 (ja) 2023-04-24
CO2018007355A2 (es) 2018-07-19
TN2019000275A1 (en) 2021-05-07
MX2018007424A (es) 2018-09-21
BR112018012096A2 (pt) 2018-11-27
CA3008267A1 (en) 2017-06-22
TW201731871A (zh) 2017-09-16
WO2017106383A4 (en) 2017-09-08
EP3390444A1 (en) 2018-10-24
AU2024200534A1 (en) 2024-04-11
ZA201904491B (en) 2020-03-25
AU2016370659B2 (en) 2024-02-15
JP2019502692A (ja) 2019-01-31
IL259847A (en) 2018-07-31
SG10201912002YA (en) 2020-02-27
CR20180365A (es) 2018-09-28
UY37027A (es) 2017-06-30
JO3816B1 (ar) 2021-01-31
PH12018501284A1 (en) 2019-01-28
KR20180099723A (ko) 2018-09-05
MA44060A (fr) 2018-10-24
EA201891322A1 (ru) 2019-01-31
AU2016370659A1 (en) 2018-06-28
WO2017106383A1 (en) 2017-06-22
CL2023002597A1 (es) 2024-03-15
SG11201804857WA (en) 2018-07-30
CN109311971A (zh) 2019-02-05
TWI799368B (zh) 2023-04-21
US11104745B2 (en) 2021-08-31

Similar Documents

Publication Publication Date Title
CL2021001179A1 (es) Anticuerpos específicos para tl1a y ácidos nucleicos que los codifican (divisional de la solicitud no. 201801596).
CL2020003409A1 (es) Moléculas de unión específicas para cd73 y métodos de fabricación de las mismas (divisional de la solicitud no. 201701154)
ECSP19026178A (es) Anticuerpos anti-pd-1 y sus usos
CL2019000061A1 (es) Anticuerpo para anti-claudin 18a2 y su utilización.
CL2019003114A1 (es) Anticuerpos anti–tau y métodos de uso (divisional solicitud 201703063)
CR20190330A (es) Anticuerpos anti-ox40 y sus usos
CR20190271A (es) Anticuerpos antitau y métodos de uso
ECSP18094829A (es) Anticuerpos anti-cd40 y sus usos
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
SV2018005684A (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
ECSP18008905A (es) Tricíclicos sustituidos y método para usarlos.
DOP2018000181A (es) Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina
BR112019012342A2 (pt) anticorpos il-11
AR105634A1 (es) Anticuerpos que se unen a il 8 y sus usos
BR112019012343A2 (pt) anticorpos il-11ra
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CL2020000946A1 (es) Métodos y composiciones para la producción de trifosfato de nucleosido y ácido ribonucleico
ECSP17023281A (es) Inhibidores de mk2 y sus usos
CL2019000508A1 (es) Formulaciones, kits y métodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentrados.
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso